International Clinical Trial: A Prospective, Single-Arm Clinical Study of Transarterial Chemoembolization (TACE) Followed by Ablation in Combination with Camrelizumab and Apatinib for the Treatment of Giant Hepatocellular Carcinoma

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133729) titled 'A Prospective, Single-Arm Clinical Study of Transarterial Chemoembolization (TACE) Followed by Ablation in Combination with Camrelizumab and Apatinib for the Treatment of Giant Hepatocellular Carcinoma' on Oct. 3.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Peking University First Hospital

Condition: Liver Cancer

Intervention: Experimental group:Camrelizumab administered by intravenous infusion (no prophylactic medication required), at a fixed dose of 200 mg, with each infusion lasting 30 minutes (no less than 20 minutes and no more than 60 minutes), once every 3 weeks Apatini...